Compare Fulford India with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs AUROBINDO PHARMA - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA AUROBINDO PHARMA FULFORD INDIA/
AUROBINDO PHARMA
 
P/E (TTM) x 398.8 11.0 3,628.6% View Chart
P/BV x 6.2 2.4 260.3% View Chart
Dividend Yield % 0.1 0.5 16.1%  

Financials

 FULFORD INDIA   AUROBINDO PHARMA
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
AUROBINDO PHARMA
Mar-18
FULFORD INDIA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs942809 116.4%   
Low Rs450504 89.3%   
Sales per share (Unadj.) Rs691.4281.1 246.0%  
Earnings per share (Unadj.) Rs11.541.4 27.7%  
Cash flow per share (Unadj.) Rs15.450.9 30.2%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.30.4 75.5%  
Book value per share (Unadj.) Rs380.0199.4 190.6%  
Shares outstanding (eoy) m3.90585.88 0.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.02.3 43.1%   
Avg P/E ratio x60.715.9 382.5%  
P/CF ratio (eoy) x45.312.9 351.2%  
Price / Book Value ratio x1.83.3 55.6%  
Dividend payout %17.46.0 288.7%   
Avg Mkt Cap Rs m2,714384,630 0.7%   
No. of employees `0000.417.3 2.6%   
Total wages/salary Rs m50521,308 2.4%   
Avg. sales/employee Rs Th6,073.09,500.7 63.9%   
Avg. wages/employee Rs Th1,137.41,229.4 92.5%   
Avg. net profit/employee Rs Th100.71,397.9 7.2%   
INCOME DATA
Net Sales Rs m2,696164,666 1.6%  
Other income Rs m1251,020 12.3%   
Total revenues Rs m2,822165,686 1.7%   
Gross profit Rs m-4637,718 -0.1%  
Depreciation Rs m155,580 0.3%   
Interest Rs m10777 1.2%   
Profit before tax Rs m5432,380 0.2%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m108,183 0.1%   
Profit after tax Rs m4524,229 0.2%  
Gross profit margin %-1.722.9 -7.5%  
Effective tax rate %17.725.3 70.0%   
Net profit margin %1.714.7 11.3%  
BALANCE SHEET DATA
Current assets Rs m1,738121,878 1.4%   
Current liabilities Rs m54586,806 0.6%   
Net working cap to sales %44.321.3 207.8%  
Current ratio x3.21.4 227.3%  
Inventory Days Days48130 37.3%  
Debtors Days Days468 6.3%  
Net fixed assets Rs m1281,037 0.0%   
Share capital Rs m39586 6.7%   
"Free" reserves Rs m1,443116,218 1.2%   
Net worth Rs m1,482116,804 1.3%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m2,077211,052 1.0%  
Interest coverage x6.742.7 15.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.8 166.4%   
Return on assets %2.611.8 22.0%  
Return on equity %3.020.7 14.5%  
Return on capital %4.327.4 15.7%  
Exports to sales %00-   
Imports to sales %24.50-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659NA-   
Fx inflow Rs m1780,727 0.0%   
Fx outflow Rs m67334,700 1.9%   
Net fx Rs m-65646,027 -1.4%   
CASH FLOW
From Operations Rs m9019,548 0.5%  
From Investments Rs m105-19,570 -0.5%  
From Financial Activity Rs m-148,642 -0.2%  
Net Cashflow Rs m1818,922 2.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 8.0 47.8%  
FIIs % 0.1 27.7 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 10.2 207.8%  
Shareholders   4,783 69,601 6.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON   PFIZER  ALKEM LABORATORIES  

Compare FULFORD INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS